Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06144736

PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND

PRIMETEST II - Phase II Trial to Prospectively Test New Predictors for Recurrence in Patients With Clinical Stage II A/B Seminoma Treated With RA-RPLND

Sponsor: Heinrich-Heine University, Duesseldorf

Conditions Seminoma

Interventions Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin Robot-assisted retroperitoneal lymph node dissection

Updated 5 times since 2023 Last updated: Sep 9, 2025 Started: Aug 28, 2023 Primary completion: Aug 31, 2026 Completion: Aug 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Seminoma, this trial is actively recruiting participants. The trial is conducted by Heinrich-Heine University, Duesseldorf and has accumulated 5 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Sep 2024 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Dec 2023 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Aug 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Heinrich-Heine University, Duesseldorf

Data source: Heinrich-Heine University, Duesseldorf

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Düsseldorf, Germany